redspeed
24 hours ago
Why is IBIO stock going down?
ChatGPT said:
iBio Inc. (IBIO) has experienced a decline in its stock price due to several factors:?
Public Offering at a Discounted Price: In December 2023, iBio announced a public offering of 2.25 million shares at $2 each, significantly below the prior closing price of $2.70. This offering raised concerns about shareholder dilution, contributing to a 41% drop in stock price at that time.
INVESTORPLACE
?
Reverse Stock Split: In November 2023, the company executed a 20-to-1 reverse stock split, reducing the number of outstanding shares from approximately 28.1 million to 1.4 million. While reverse splits can increase share prices temporarily, they often signal financial distress and can lead to decreased investor confidence. ?
Financial Performance and Cash Flow Concerns: For the fiscal year ending June 30, 2024, iBio reported a net loss of $24.9 million, an improvement from the previous year's loss but still indicative of ongoing financial challenges. The company also faced negative cash flows, raising concerns about its ability to fund operations and growth initiatives. ?
Insider Selling and Dilution Risks: There have been instances of insider stock sales, which can be perceived negatively by investors. Additionally, previous agreements, such as those with Aspire Capital Fund and Lincoln Park Capital Fund, involve the issuance of substantial shares, potentially diluting existing shareholders and impacting stock value. ?
These factors collectively have contributed to the downward pressure on iBio's stock price.
redspeed
1 day ago
On February 10, 2025 PR they said revenue of $0.2 million was reported for services provided to a collaborative partner during the quarter ended Dec. 31, 2024.
R&D and G&A expenses for the second quarter of fiscal 2025 totaled approximately $4.6 million
Cash, cash equivalents and restricted cash as of Dec. 31, 2024, was approximately $7.2 million, inclusive of $0.2 million of restricted cash.
Lets be generous and add the $650,000 by the members of its Board of Directors and Officers
Why only $650K though for this "Gold Mine".
Was it to give the illusion to save their RSUs and Options?
Using 'simple math' the company had $7.2M in cash in December. Add the $650K
They are currently throwing over $1.5M out the window per month.
That gives the company approximately cash for FIVE months
Jan., Feb. Mar, Apr, May
Who is going to pony up $10M more to keep the boat afloat this year?
JoeForkeyBolo
3 days ago
Why is iHub still showing AMEX?
Probably because the $6.33 price for the last trade on AMEX is a hell of a lot better than the current $4.50 price on NASDAQ, and IHUB wants to keep IBIO investors from sinking into depression. IBIO share price has been on a steady decline since the move to the new exchange.
Some have posted the move to the NASDAQ exchange would be "revealing", while the company CEO tried to spin it as a positive move for investors. So far it's very revealing.
Perhaps someone is investing another six figures here, loading up on cheaper shares as the price continues lower, assuming they have that much remaining after previous catastrophic investments... clicking the BUY button with one hand while eating a slice of delicious Domino's pizza with the other hand.
Notice the sour look on the investor's face. Even a slice of delicious Domino's pizza can't change the fact they've picked another loser investment, and trying to save face by averaging down as the share price continues to tank. No zip code change in this guy's future.
redspeed
7 days ago
What?
Great to hear from you.
"Your bs is done with IBIO Sir!!!"
I 'do' get why you are responding on Monday, January 20, 2025 12:32:13 AM
to a post I made SIX MONTHS EARLIER on Friday, July 26, 2024 7:57:30 AM LOL
Seems to be a 6 month reaction in hindsight, but I welcome and will return the favor in spaces
where I said...
Toast...
"We are filing this registration statement with the Securities and Exchange Commission (the “SEC”) using a “shelf” registration process. Under this registered “shelf,” in the future, we may, from time to time, sell any combination of the securities described herein, in one or more offerings, up to a maximum aggregate offering price of $150,000,000. This prospectus provides you with a general description of the securities."
Hope spring internal.
Some have invested their kids tuition into IBIO only to send them to maid school.
Risk / Reward
JoeForkeyBolo
3 weeks ago
To be fair, I made the following request to the ChatGPT AI model:
Compare the listing requirements for NYSE American and NASDAQ Capital Markets, including requirements for a company on either exchange to remain listed.
———————————————————————————————
A transfer from NYSE American to NASDAQ Capital Market can be viewed from multiple perspectives, depending on the company's financial situation, growth strategy, and investor perception.
Is It Easier to Meet NASDAQ Capital Market Requirements?
In general, NASDAQ Capital Market has slightly higher requirements than NYSE American in some aspects, such as:
• Stock Price: NASDAQ requires a minimum of $4/share for initial listing, while NYSE American allows as low as $2/share under some standards.
• Stockholders' Equity: NASDAQ requires at least $5 million for initial listing (under the Equity Standard), while NYSE American requires $4–$6 million depending on the listing path.
• Market Capitalization: NYSE American has an initial market cap requirement of $50 million (or lower in alternative standards), while NASDAQ Capital Market has a lower continued listing requirement at $35 million.
If a company is struggling to meet NYSE American's continued listing requirements but still qualifies for NASDAQ Capital Market, the move can help avoid delisting and provide a fresh start on a well-recognized exchange.
How is the Move Perceived?
• Neutral or Positive: If the transfer is due to a strategic decision (e.g., better alignment with NASDAQ’s technology-focused investor base), it may be seen as a neutral or positive move.
• Negative: If the move happens because the company fails to meet NYSE American’s requirements, investors might see it as a downgrade or a sign of financial trouble.
Other Considerations
• NASDAQ has a more tech-friendly reputation: If the company operates in tech, biotech, or growth industries, moving to NASDAQ might attract more institutional and retail investors.
• Market Perception Matters: Investors may view a transfer as an attempt to avoid delisting if the company struggles to meet NYSE American’s standards.
• NASDAQ offers lower listing fees: Annual fees on NASDAQ Capital Market tend to be lower than on NYSE American.
Final Verdict
• If the company voluntarily moves for strategic reasons, it’s a neutral or positive shift.
• If the move is forced due to non-compliance, it may be seen as a negative signal by investors.
• While the requirements aren’t significantly easier, NASDAQ Capital Market does offer a lower continued market cap threshold, which might help struggling companies stay listed.
JoeForkeyBolo
3 weeks ago
This is a transfer from NYSE to NASDAQ. Not the same thing as uplisting. NASDAQ's Capital Market requirements are less stringent than NYSE American and easier for IBIO to remain listed on a national exchange. In that regard it could be viewed as a necessary move for the company. The last paragraph below spins it as a positive move, but that's what companies do. Maybe it will be. But no one should be fooled into believing this is an uplisting that occurs when a company is moving to the next higher tier of corporate and financial performance.
March 4th is iBio's Nasdaq uplisting
iBio to Begin Trading on the Nasdaq Stock Exchange
SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, today announced that iBio’s common stock has been approved for listing on the Nasdaq Capital Market and iBio will transfer its stock exchange listing to Nasdaq Capital Market from the NYSE American. The Company expects to begin trading as a Nasdaq-listed company on Mar 4, 2025, and will continue to trade under the symbol “IBIO.” The Company’s common stock will continue to trade on the NYSE American until the market close on Mar 3, 2025.
Martin Brenner, Ph.D., DVM, iBio’s CEO and Chief Scientific Officer, commented, “We are pleased to announce our listing on the Nasdaq Capital Market and to join a community of leading biotech companies. We believe the move to Nasdaq will improve the visibility of our common stock, enhance trading liquidity in our shares, and provide us with greater exposure to institutional investors.”
https://ir.ibioinc.com/news-events/press-releases/detail/234/ibio-to-begin-trading-on-the-nasdaq-stock-exchange
tw0122
3 weeks ago
IBIO $5.68 coming to the rescue so munch for Chinese take out.. Bird Flu in Cats New Jersey
Two domestic cats in New Jersey have tested positive for the highly pathogenic avian influenza (H5N1) in Hunterdon County. One feral cat developed severe disease, including neurologic signs, and was euthanized. Another indoor-outdoor cat also tested positive, and tests on other cats on the property are pending.Additional Details:Symptoms in Cats: Clinical signs of bird flu in cats can include respiratory signs (discharge from the eyes and mouth, sneezing, coughing, difficulty breathing) and neurologic signs.Transmission: Cats can contract the virus through exposure to infected birds or other animals, contaminated environments, or by consuming raw/undercooked meat or milk from infected sources.Prevention: Pet owners are advised to avoid feeding cats raw milk or meat, avoid contact with sick or dead birds and wildlife, and thoroughly wash hands and change clothes after handling sick animals.Human Risk: While the risk of H5N1 infection to the general population remains low, close contact with infected animals can pose a risk. No human cases have been reported in New Jersey.Reporting: New Jersey residents should contact their veterinarian if they have concerns about their pets. Suspect feline cases should be reported to the New Jersey Department of Health at 609-826-4872 or zoonoticrn@doh.nj.gov.
tw0122
3 weeks ago
Insiders got lots of free shares and 13GS show some big owners invested ..
424B3 (Prospectus) 2025-02-11iBio, Inc. (IBIO) 8-K (Current report) 2025-02-102025-02-10iBio, Inc. (IBIO) EFFECT (SEC order) 2025-02-10iBio, Inc. (IBIO) 10-Q (Quarterly report) 2025-02-102024-12-31iBio, Inc. (IBIO) S-8 (Registration statement) 2025-01-31iBio, Inc. (IBIO) S-3 (Registration statement) 2025-01-31iBio, Inc. (IBIO) SCHEDULE 13G/A 2025-01-30iBio, Inc. (IBIO)
Crutcher Patrick J SCHEDULE 13G 2025-01-29iBio, Inc. (IBIO)
Crutcher Patrick J 4 (Insider trading report) 2025-01-132025-01-10Banjak Marc
iBio, Inc. 8-K (Current report) 2025-01-132025-01-10iBio, Inc. (IBIO) 4 (Insider trading report) 2025-01-132025-01-10Duran Felipe
iBio, Inc. 4 (Insider trading report) 2025-01-132025-01-10Parada Antonio Bernardino Guimaraes
iBio, Inc. 4 (Insider trading report) 2025-01-132025-01-10Brenner Martin
iBio, Inc. 4 (Insider trading report) 2025-01-132025-01-10Sender Gary
iBio, Inc. 4 (Insider trading report) 2025-01-132025-01-10Arkowitz David
iBio, Inc. 4 (Insider trading report) 2025-01-132025-01-10Clark William D
iBio, Inc. 8-K (Current report) 2025-01-102025-01-10iBio, Inc. (IBIO) SCHEDULE 13G/A 2025-01-03iBio, Inc. (IBIO)
SABBY MANAGEMENT, LLC 8-K (Current report) 2025-01-022024-12-31iBio, Inc. (IBIO) 4 (Insider trading report) 2024-12-092024-11-21Parada Antonio Bernardino Guimaraes
iBio, Inc. 3 (Initial insider holdings report) 2024-12-092024-11-21Parada Antonio Bernardino Guimaraes
iBio, Inc. 4 (Insider trading report) 2024-11-252024-11-21Sender Gary
iBio, Inc. 8-K (Current report) 2024-11-252024-11-21iBio, Inc. (IBIO) 4 (Insider trading report) 2024-11-252024-11-21Schimmelpennink Evert B.
iBio, Inc. 4 (Insider trading report) 2024-11-252024-11-21Kropotova Alexandra
iBio, Inc. 4 (Insider trading report) 2024-11-252024-11-21Clark William D
iBio, Inc. 4 (Insider trading report) 2024-11-252024-11-21Arkowitz David
iBio, Inc. 3 (Initial insider holdings report) 2024-11-252024-11-21Arkowitz David
iBio, Inc. SC 13G (Beneficial ownership report) 2024-11-14iBio, Inc. (IBIO)
Ikarian Capital, LLC SC 13G/A (Beneficial ownership report) 2024-11-14iBio, Inc. (IBIO)
ADAR1 Capital Management, LLC
JoeForkeyBolo
4 weeks ago
This story was initially reported in the U.K.'s Daily Mail, which is regarded as a tabloid. Here's how the Daily Mail is described in Wikipedia and many other sources. I'm taking this story with a lot of skepticism until I see it reported by more reliable sources (if there is such a thing in today's news services). If true, I stand to profit enormously with one of my investments, but for humanity's sake I hope this is tabloid fiction.
"The Daily Mail has been criticized for its unreliability, its printing of sensationalist and inaccurate scare stories about science and medical research, and for instances of plagiarism and copyright infringement."[/I] – Wikipedia
Top Penny
2 months ago
Otsuka
On February 25, 2024, the Company entered into the PD-1 Purchase Agreement with Otsuka pursuant to which the Company sold and assigned to Otsuka, and Otsuka purchased and assumed, all intellectual property rights directly related to the Company’s PD-1 Assets developed or held for development. The Company received an upfront payment of $1.0 million in cash at closing which is reported as a gain in the fiscal year ended June 30, 2024. The Company will also be eligible to receive additional contingent cash payments totaling up to $52.5 million upon the achievement of certain pre-specified clinical development and commercial milestones. The Company will recognize the potential milestone payments at the earlier of when the contingent consideration is realized or is realizable.
Affiliates of Eastern Capital Limited
On November 1, 2021, the Company and its subsidiary, iBio CDMO LLC (“iBio CDMO”, and collectively with the Company, the “Purchaser”) entered into a series of agreements (the “Transaction”) with College Station Investors LLC (“College Station”), and Bryan Capital Investors LLC (“Bryan Capital” and, collectively with College Station, “Seller”), each affiliates of Eastern Capital Limited (“Eastern,” a former significant stockholder of the Company) described in more detail below whereby in exchange for a certain cash payment and a warrant the Company:
(i) acquired both the Facility where iBio CDMO at that time and currently conducts business and also the rights as the tenant in the Facility’s ground lease;
(ii) acquired all of the equity owned by one of the affiliates of Eastern in the Company and iBio CDMO; and
(iii) otherwise terminated all agreements between the Company and the affiliates of Eastern.
The Facility is a life sciences building located on land owned by the Board of Regents of the Texas A&M University System (“Texas A&M”) and is designed and equipped for the manufacture of plant-made biopharmaceuticals. iBio CDMO had held a sublease for the Facility through 2050, subject to extension until 2060 (the “Sublease”) until the consummation of the sale of the Facility.
Level up your trading with our powerful tools and real-time insights all in one place.
JPetroInc
3 weeks ago
Monksdream
3 weeks ago
bluebird50
3 weeks ago
georgie18
1 month ago
DRHUMI
1 month ago
Hot Features
Premium
